Clive Kearon Selected Research

Venous Thrombosis (Deep-Vein Thrombosis)

1/2022	Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility.
1/2021	A simplified decision rule to rule out deep vein thrombosis using clinical assessment and D-dimer.
1/2021	Performance of two clinical scales to assess quality of life in patients with post-thrombotic syndrome.
11/2020	Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial.
1/2020	Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis.
1/2020	Clinical pre-test probability adjusted versus age-adjusted D-dimer interpretation strategy for DVT diagnosis: A diagnostic individual patient data meta-analysis.
1/2020	Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data meta-analysis.
10/2019	Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial.
10/2019	Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial.
4/2019	Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral-Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Clive Kearon Research Topics

Disease

51	Venous Thromboembolism 07/2022 - 01/2002
44	Hemorrhage 07/2022 - 09/2002
34	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 01/2002
24	Pulmonary Embolism 01/2022 - 01/2003
24	Thrombosis (Thrombus) 01/2021 - 03/2003
15	Neoplasms (Cancer) 01/2020 - 01/2003
7	Postthrombotic Syndrome 12/2021 - 06/2008
5	Thromboembolism 01/2021 - 08/2003
5	Stroke (Strokes) 01/2018 - 09/2002
4	Atrial Fibrillation 01/2021 - 01/2003
3	Pain (Aches) 11/2020 - 01/2008
3	Myocardial Infarction 01/2018 - 04/2014
3	Hypotension (Low Blood Pressure) 02/2016 - 02/2012
3	Thrombophilia 09/2012 - 01/2004
3	Ischemic Stroke 06/2008 - 09/2004
1	Venous Insufficiency 01/2019
1	Hyperpigmentation 03/2017
1	Obesity 03/2017
1	Edema (Dropsy) 03/2017
1	Ischemia 12/2016
1	Heart Arrest (Cardiac Arrest) 04/2014
1	Sepsis (Septicemia) 03/2014
1	Myocardial Ischemia (Ischemic Heart Diseases) 03/2014
1	Acute Coronary Syndrome 02/2013
1	ST Elevation Myocardial Infarction 06/2008
1	Body Weight (Weight, Body) 02/2007
1	Oral Hemorrhage 02/2006
1	Fatigue 05/2005
1	Inflammation (Inflammations) 01/2004
1	Hypoxia (Hypoxemia) 01/2004
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 09/2003
1	Embolism (Embolus) 08/2003

Drug/Important Bio-Agent (IBA)

43	AnticoagulantsIBA 07/2022 - 01/2002
21	fibrin fragment D (D-dimer)IBA 11/2021 - 01/2003
17	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 09/2002
16	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2021 - 01/2003
9	Vitamin K FDA Link 02/2016 - 08/2004
7	Dabigatran FDA Link 01/2018 - 12/2009
7	Heparin (Liquaemin)FDA LinkGeneric 06/2008 - 08/2003
6	Antiphospholipid AntibodiesIBA 01/2020 - 06/2003
5	factor V LeidenIBA 09/2014 - 06/2003
4	RivaroxabanIBA 11/2020 - 02/2012
3	Hemoglobins (Hemoglobin)IBA 01/2022 - 08/2017
3	Prothrombin (Factor II)IBA 09/2014 - 12/2009
3	Fondaparinux (Arixtra)FDA Link 02/2012 - 06/2008
2	CreatinineIBA 01/2022 - 10/2021
2	Pharmaceutical PreparationsIBA 01/2018 - 05/2005
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2016 - 04/2014
2	Protein CIBA 11/2013 - 09/2012
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 09/2004 - 03/2003
1	Rosuvastatin Calcium (Crestor)FDA Link 01/2022
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022
1	Dalteparin (Dalteparin Sodium)FDA Link 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2020
1	Nucleosomes (Nucleosome)IBA 01/2020
1	Dihydrotachysterol (AT 10)IBA 01/2019
1	Omeprazole (Prilosec)FDA LinkGeneric 01/2018
1	Tissue Plasminogen Activator (Alteplase)FDA Link 12/2017
1	edoxabanIBA 02/2016
1	apixabanIBA 02/2016
1	Clonidine (ST 155)FDA LinkGeneric 04/2014
1	TroponinIBA 03/2014
1	Troponin T (Troponin T1)IBA 03/2014
1	Endothelial Protein C ReceptorIBA 11/2013
1	Amiodarone (Amiodarona)FDA LinkGeneric 08/2013
1	RHO(D) antibody (anti-D)IBA 09/2012
1	AntithrombinsIBA 09/2012
1	Immunoglobulin Fab FragmentsIBA 09/2012
1	Protein SIBA 09/2012
1	Thrombin FDA Link 12/2009
1	HirudinsIBA 06/2008
1	HomocysteineIBA 06/2007
1	Folic Acid (Vitamin M)FDA LinkGeneric 06/2007
1	VitaminsIBA 06/2007
1	Enoxaparin (Lovenox)FDA LinkGeneric 02/2007
1	E-SelectinIBA 01/2004
1	P-selectin ligand proteinIBA 01/2004
1	P-SelectinIBA 01/2004
1	Thromboplastin (Tissue Factor)IBA 01/2004
1	LatexIBA 05/2003

Therapy/Procedure

42	Therapeutics 07/2022 - 01/2002
11	Catheters 01/2021 - 06/2008
5	Duration of Therapy 07/2022 - 03/2003
5	Compression Stockings 04/2013 - 06/2008
4	Secondary Prevention 12/2021 - 01/2003
4	Thrombolytic Therapy 01/2017 - 06/2008
2	Blood Transfusion (Blood Transfusions) 01/2021 - 01/2021
2	Intravenous Infusions 09/2007 - 08/2006
1	Contraindications 01/2020
1	Central Venous Catheters 07/2018
1	Surgical Amputation (Amputations) 01/2018
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 11/2011
1	Intermittent Pneumatic Compression Devices 01/2011
1	Bed Rest (Bedrest) 01/2008
1	Length of Stay 09/2006
1	Orthopedic Procedures 12/2003
1	Arthroplasty 06/2003
1	Hip Replacement Arthroplasty (Total Hip Replacement) 06/2003
1	Stroke Rehabilitation 09/2002